Publication | Closed Access

The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy

OncologyMedicineImmunologyHematologyPathologyHnscc PatientsClinical ChemistryLaboratory MedicineTumor MicroenvironmentCancer Research